首页> 美国卫生研究院文献>Cancers >Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy
【2h】

Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy

机译:IPF和肺癌患者KL-6血清浓度和抗纤维化治疗治疗的IPF患者的KL-6序列测量

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Evaluation of the prognostic significance of serial measurements of serum concentrations of Krebs von den Lungen-6 (KL-6) showed that an annual increment in KL-6 exceeding a threshold amount was an independent risk factor for progressive disease and poor prognosis. No literature data are available on long-term KL-6 measurements in the follow-up of IPF patients treated with Nintedanib. The aim of this study is to serially analyze KL-6 in idiopathic pulmonary fibrosis (IPF) patients after 24 months of Nintedanib and to investigate its biomarker potential in patients with IPF and lung cancer with respect to fibrotic hypersensitivity pneumonitis patients, pulmonary fibrosis associated with autoimmune diseases group and healthy controls.
机译:评估血清血清血清肺植入-6(KL-6)的序列测量的预后意义表明,超过阈值量的KL-6年增长率是渐进性疾病和预后差的独立危险因素。没有文献数据可以在用尼德尼布治疗的IPF患者的随访中提供长期KL-6测量。本研究的目的是在尼丁尼布24个月后连续分析患有特发性肺纤维化(IPF)患者的KL-6,并研究其对IPF和肺癌患者的生物标志物潜力,相对于纤维化过敏肺炎患者,肺纤维化有关的肺纤维化自身免疫疾病组和健康控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号